Nabriva Therapeutics
在场
Nabriva Therapeutics 是一家在股票代码 NBRV (US) 下上市的公司。
高管
查看带有其 11 名主要高管的组织结构图
Nabriva Therapeutics 搜索最多的简介
- Christopher Naftzger, Interim Chief Executive Officer, General Cou...
- Mark Corrigan, Director
- Stephen Webster, Director
创建提醒
跟踪 Nabriva Therapeutics 的高管变动
生物技术
Nabriva Therapeutics 拥有 2,317 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Evommune 刚刚宣布为 115 筹款数百万美元。 (公布2024十一月4号).
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
生物技术 行业的其他推荐联系人
消息
Nabriva Therapeutics 的最新新闻稿
- Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update | Nabriva Therapeutics
- Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022 | Nabriva Therapeutics
- Nabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim Pharmaceuticals | Nabriva Therapeutics
- Nabriva Therapeutics to Present at the H.C. Wainwright Global Investment Conference | Nabriva Therapeutics
- Nabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update | Nabriva Therapeutics
- Nabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S. Through the End of 2026 | Nabriva Therapeutics
- Nabriva Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Highlights on May 5, 2022 | Nabriva Therapeutics
- News & Publications | Nabriva.com
- News & Publications | Nabriva.com
- Nabriva’s XENLETA Demonstrates High Efficacy in Patients of Advanced Age with Community-Acquired Bacterial Pneumonia (CABP) | Nabriva Therapeutics
- View more press releases Close
通过电子邮件
